Terms of USE 1. General Conditions This website is owned and operated by Paradigm Biopharmaceuticals Limited (PAR) ACN 169 346 963. Your access to this

Thank you for joining our mailing list. Home

Drug Development Faq Why do diseases like OA remain an unmet need? Successful treatment and management of disease or injury involving inflammation remains a great

Product Development The cost and complexity of starting with a new molecule is high, encourages iterative progress and reduces the potential for genuine discovery. Looking

Privacy Policy Paradigm Biopharmaceuticals Ltd. is committed to protecting the privacy of all persons with whom it communicates whether through its site or otherwise. This

Performance & Progress Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs. Paradigm

Pentosan POLYSULFATE SODIUM Pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to

Resources & Events Paradigm conducts research and development days, investor roadshows, investor days, virtual conferences and webinars and clinical updates. To stay up to date

Thank you for your enquiry. Home